Grimes & Company’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Grimes & Company's VRTX Position: Q3 2026 in Review
Grimes & Company increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q3 2026, buying an estimated $5.63K and bringing the position to 770 shares worth $403K. The position accounts for 0.01% of the portfolio, ranked #343.
Grimes & Company first reported a position in VRTX in Q1 2022 and has held it in 13 quarters since. 1,722 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Grimes & Company held 770 shares of Vertex Pharmaceuticals worth $403K as of Q3 2026.
- Grimes & Company bought 11 Vertex Pharmaceuticals shares in Q3 2026, an estimated $5.63K.
- Vertex Pharmaceuticals made up 0.01% of Grimes & Company's portfolio in Q3 2026, its #343 holding.
- Grimes & Company first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
- 1,722 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Grimes & Company's 13F filing for Q3 2026, filed 29 Oct 2026.